UCB : BIMZELX 3-Year Results Confirm Sustained Efficacy In Psoriatic And Axial Spondyloarthritis
12/6 04:24
(RTTNews) - UCB (UCB) announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axia...